




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> A61K 39/106, C07K 15/04 C12N 9/78, 15/55, G01N 33/573 G01N 33/569	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/09823</b>  <b>(43) International Publication Date:</b> 11 May 1994 (11.05.94)
<b>(21) International Application Number:</b> PCT/EP93/03059 <b>(22) International Filing Date:</b> 2 November 1993 (02.11.93)  <b>(30) Priority data:</b> 07/970,996 3 November 1992 (03.11.92) US 08/085,938 6 July 1993 (06.07.93) US  <b>(71) Applicant (for all designated States except US):</b> FONDATION POUR LA RECHERCHE DES MALADIES GASTRO-INTESTINALES: GASTROFONDS MANDATARIA FIDUCIAIRE SA [CH/CH]; Rue Saint-Pierre 3, CH-1003 Lausanne (CH).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> MICHETTI, Pierre [CH/CH]; BLUM, André [CH/CH]; DAVIN, Catherine [FR/CH]; Division de Gastro-entérologie, BH10-CHUV, CH-1011 Lausanne (CH). HAAS, Rainer [DE/DE]; Max Planck Institut für Biologie, Abteilung Infektionsbiologie, Spemannstrasse 34, D-Tübingen (DE). CORTESY-THEULAZ, Irène [CH/CH]; Division de Gastro-entérologie, BH10-CHUV, CH-1011 Lausanne (CH). KRAEHNBUHL, Jean-Pierre [CH/CH]; Institut de Biochimie de l'Université de Lausanne et ISREC, CH-1066 Epalinges (CH). SARAGA, Emilia [CH/CH]; Institut universitaire de Pathologie, Rue du Bugnon 25, CH-1011 Lausanne (CH).		<b>(74) Agent:</b> REVERDIN, André; Katzarov S.A., 19, rue des Epinettes, CH-1227 Genève (CH).  <b>(81) Designated States:</b> AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: UREASE-BASED VACCINE AGAINST HELICOBACTER INFECTION

## GROUP B: MICE PROTECTED AFTER IMMUNIZATION WITH UREASE



## (57) Abstract

Method of eliciting in a mammalian host a protective immune response to *Helicobacter* infection by administering to the host an immunogenically effective amount of a *Helicobacter* urease or urease subunits as antigen. Vaccine compositions are also provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**UREASE-BASED VACCINE AGAINST HELICOBACTER  
INFECTION**

5       The present invention relates to the prevention and treatment of gastric infection in mammals, including humans. More particularly, the present invention relates to a vaccine suitable for use in the prevention and treatment of *Helicobacter* infection in mammals, including humans, and to a method of treatment of humans suffering from gastric infection, its  
10 consequences such as chronic gastritis or peptic ulcer, and prevention of gastric cancer.

**BACKGROUND**

15       *Helicobacter* infection of human gastric epithelium cause gastritis, are a major factor in the development of peptic ulcers and gastric lymphoma, and may be a risk factor for the development of gastric cancer [1-3]. The most frequent infection agent is *Helicobacter pylori*, followed at a much lower frequency by *Helicobacter heilmannii*. *H. pylori* is a slender S-  
20 shaped gram negative microorganism, which is routinely recovered from gastric biopsies of adults and children with histologic evidence of gastritis or peptic ulceration. Evidence for a causal relationship between *H. pylori* and gastroduodenal disease comes from studies in human volunteers, patients with ulcers and gastric cancer, gnotobiotic pigs, and germ-free  
25 rodents. Regarding etiology, Koch's postulates were satisfied by creating histologically confirmed gastritis in previously uninfected individuals following consumption of viable microorganisms [4-11], and by treatment to eradicate *H. pylori*, with resolution of the gastritis and, in patients with peptic ulcer disease, a decrease in the recurrence rate [12].

30       In spite of *in vitro* susceptibility to many antimicrobial agents, *in vitro* eradication of established *H. pylori* infections with antimicrobial agents is often difficult to achieve [13]. The microorganism is found within

the mucous coat overlying the gastric epithelium and in gastric pits. These are locations which do not appear to allow for adequate antimicrobial levels to be achieved even when antibiotics are given orally at high doses. At the present time, most authorities recommend a "triple therapy", namely a  
5 bismuth salt in combination with drugs such as tetracycline and metronidazole for 2-4 weeks. However, the effectiveness of this or other chemotherapeutic regimens remains suboptimal. Furthermore, this treatment may produce serious adverse drug reactions.

At the present time little is known regarding the role of the mucosal  
10 immune system in the stomach. The distribution of immunoglobulin (Ig) producing cells in the normal gastric antrum indicates that IgA plasma cells make up 80% of the total plasma cell population. In addition, the number of plasma IgA cells present in the gastric antrum is comparable to other mucous membranes [14, 15]. A number of studies in humans [16] and in  
15 animal models [8, 10] have demonstrated specific IgG and IgA responses in serum and in gastric secretions in response to *Helicobacter* infection. However, the observation that *H. pylori* infection persists as a chronic infection for years, despite inducing a local and systematic immune response, is not encouraging the development of immunization strategies.

20 Lee et al reported the ability to infect germ-free rodents with *Helicobacter felis*, a bacterium closely related to *H. pylori*, and reproducible document histologic gastritis [9, 10]. Since then, this bacterium-host pairing has been accepted as a good model to study *Helicobacter*-mediated gastritis and its initiating factors [17]. Czinn et al have shown that repetitive oral  
25 immunization with a crude lysate of *H. pylori* plus cholera toxin adjuvant induces a vigorous gastrointestinal IgA anti-*H. pylori* response in mice and ferrets [13]. In addition, Chen et al and Czinn et al have recently reported that oral immunization with a crude lysate of *H. felis* induced protection against *H. felis* infection in mice [21, 22]. The exact nature of the  
30 antigen(s) responsible for the induction of this protection, however, had not been determined, and no information suggested that the protective antigen(s) of *H. felis* that induced protection against this pathogen would

induce a cross-reactive protection extending to another *Helicobacter* species.

We have demonstrated for the first time that *H. pylori* and *H. felis* sonicates and showing that some of these antibodies, directed against *H. pylori*, would crossreact with *H. felis* and vice versa [24, 25]. The basis for these cross-reactivities were unknown.

Based on the homology existing between the different known urease amino acid sequences, it has been proposed that urease could be used as a vaccine against *H. pylori* [26]. Nevertheless, cross-reactivity is not the rule. Guo and Liu have shown years ago that ureases of *Proteus mirabilis*, *Proteus vulgaris* and *Providencia rettgeri* show cross-reactivity to each other, while ureases of jack bean and *Morganella morganii* are immunologically distinct from the three former ureases [23]. Even if an antigenic cross-reactivity of *H. pylori* urease with other *Helicobacter* ureases was a reasonable postulate, no data existed demonstrating that this was really the case until we showed that some *H. felis* monoclonal antibodies crossreacted with *H. pylori* urease [25]. J. Pappo has further demonstrated that mice which have been infected by *H. felis* produce antibodies which crossreact with *H. pylori* urease but not jack bean urease (J. Pappo, unpublished data, 1993).

The use of *H. pylori* urease, or of related ureases, as a vaccine against *H. pylori* infection has previously been proposed by A. Labigne in EPO 367,644 [28]. However, that application contains no evidence of vaccination of any mammal against any *Helicobacter* infection with urease.

Moreover, while sequence homology with other bacterial ureases might support the use of urease as a vaccine candidate against *H. pylori* infection, the current knowledge of human *H. pylori* infection would certainly not. First, despite the fact that infected individuals often mount a strong antibody response to urease, the anti-urease immune response does not result in clearance or control of the infection. Secondly, *H. pylori* is able to transport urease out of the cell and to shed it from its surface [19, 20]. Thus, urease may not represent an appropriate target for the

development of a protective mucosal immune response. Indeed, mucosal immune protection is thought to be mainly mediated by secretory IgA, the agglutinating activity of which would be impaired when the recognized antigen can be shed by the target pathogen and thereby serve as a decoy for the protective antibody. Thirdly, urease appears to be toxic for epithelial cells in culture, and has been suspected to play a role in mucous degradation and in peptic ulceration *in vivo*. Thus, its use as antigen may be toxic.

Nevertheless, we reasoned that this antigen could be a potentially efficient vaccine if:

- first, we would deliver it orally at a sufficiently high dose to elicit a stronger immune response than the naturally occurring one
- second, the amount of antibodies produced would be high enough to bind all the urease, shed or not shed
- third, we would use subunits of urease or a molecular species that was non-toxic.

In summary, there remains a need for effective treatment and prevention of *H. pylori*-induced gastric infection in humans. Recent data suggested the possibility to generate a vaccine against this infection, but have not provided a clear identification of defined antigen(s), common to all strains of *H. pylori*, that could be incorporated into a safe and effective vaccine.

In this invention, we have identified the urease antigen of *H. pylori* as a candidate vaccine and demonstrated its efficiency in an animal model. These results were unexpected in the light of the natural history *Helicobacter* infections.

### SUMMARY OF THE INVENTION

We have discovered that immunity can be induced in mammals susceptible to gastrointestinal *Helicobacter* infection by exploiting urease epitopes displayed on or about the surface of *Helicobacter* organisms and using them as a vaccine target. The immunity can be induced by

immunization with nature urease, but can also be induced with recombinant urease subunit, produced as an enzymatically inactive, therefore non-toxic form. The invention provides a method of inducing immunity to *Helicobacter* infection by administering to a mucosal surface of a mammal  
5 a polyaminoacid preparation, i.e. a mixture of peptides and/or proteins, together with an appropriate adjuvant. This polyaminoacid preparation presents a plurality of epitopes characteristic of and exhibited by a urease enzyme endogenous to the infecting *Helicobacter* organism. The administration of the polyaminoacid preparation may be performed by the  
10 oral route.

The active ingredient of the preparation may comprise natural or biosynthetic epitopes and may take various forms. A non exhaustive list of possible preparations includes purified, naturally occurring or recombinantly produced urease preparations of bacterial or other origin, digests of urease,  
15 fusion proteins comprising urease epitopes, truncated forms of urease enzyme, or peptides homologous with the aminoacid sequence of urease. Since development of immunity depends on induction of humoral and/or cellular immune responses which bind to the infecting *Helicobacter* organism, preferred preparations are those which most closely duplicate the  
20 epitopes of the urease endogenous to the infecting organism. For example, preparations displaying the epitopes of urease of *H. pylori* are preferred for administration in humans susceptible to *H. pylori*. However, in accordance with an important aspect of the invention, it has been discovered that urease from other species may be used. For example, we have shown that *H. felis*  
25 infection in mice can be prevented by administration of urease from *H. pylori*.

According to one aspect of the invention, there is provided a method of eliciting in a mammalian host a protective immune response to *Helicobacter* infection wherein an immunologically effective amount of a  
30 urease antigen capable of eliciting such a protective immune response, preferably *H. pylori* urease or *H. pylori* urease B subunit, is administered to a mucosal surface of the host.

According to another aspect of the present invention, there is provided a vaccine composition suitable for prevention of *Helicobacter* infection, comprising an effective amount of a urease antigen, preferably *H. pylori* urease or *H. pylori* urease B subunit, capable of eliciting in a host a  
5 protective immune response to *Helicobacter* infection, in association with a pharmaceutically acceptable carrier or diluent.

According to a further aspect of the present invention, there is provided a method of imparting to a mammalian host passive protection to *Helicobacter* infection, comprising administering to a mucosal surface of  
10 the host an immunologically effective amount of a urease specific antibody produced in a host immunized with a urease, preferably *H. pylori* urease or *H. pylori* urease B subunit, capable of eliciting a protective immune response to *Helicobacter* infection.

#### 15 BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be further described with reference to the accompanying drawings, in which Figures 1 through 6 are graphical representations of the results set forth in Tables 1 through 6.

#### 20 DETAILED DESCRIPTION OF THE INVENTION

The present inventors have discovered that oral administration to mice of polyaminoacid preparations exhibiting the epitopes of *H. pylori* urease gives rise to a protective immunological response against *H. felis* in  
25 mice, an animal model of generally-accepted value for the study of the immune response to *Helicobacter* infection [9]. The effect of the protective immune response is that immunized animals, when challenged with pathogen, have a greatly reduced incidence of infection, in comparison to non-immunized animals. Furthermore, the inventors have discovered that  
30 oral immunization in mice using *H. pylori* urease B subunit, produced as an enzymatically-inactive recombinant protein, gives rise to a protective immunological response in mice against *H. felis*. The effect of the



protective immune response is that immunized animals, when challenged with pathogen, have also a greatly reduced incidence of infection, in comparison to non-immunized animals which do become infected.

Thus, in a first aspect, the present invention provides a method of  
5 eliciting in a mammalian host a protective immune response to *Helicobacter* infection. The method comprises the step of administering to a mucosal surface of the mammal, including humans, an immunologically effective amount of a urease antigen, preferably *H. pylori* urease, capable of eliciting such a protective immune response.

10 In a second aspect, the present invention provides a method of eliciting in a mammalian host a protective immune response to *Helicobacter* infection. The method comprises the step of administering to a mucosal surface of the animal, including humans, an immunologically effective amount of recombinant, enzymatically inactive urease B subunit an antigen,  
15 preferably recombinant *H. pylori* urease B subunit, capable of eliciting such a protective immune response.

The invention also includes within its scope the treatment or prophylaxis of mammals, including humans, for *Helicobacter* infection, wherein an immunologically effective amount of a urease, or its subunits,  
20 capable of eliciting a protective immune response to *Helicobacter* infection, is administered to a mucosal surface of a patient. Preferably, the urease is *H. pylori* urease or *H. pylori* urease B subunit, and the urease may be administered either alone or linked to a hydroxylated calcium phosphate, for example hydroxyapatite as a carrier particle. Moreover, it is preferred to  
25 administer the *H. pylori* urease in association with a mucosal adjuvant, the B subunit of cholera toxin, muramyl dipeptide or other such adjuvants.

While not being bound by any theory, the present inventors believe that administration of the urease antigen, or B subunit thereof, to a mucosal surface stimulates the common mucosal immune system and perhaps local  
30 sites in the gastric mucosal including an immune response, including the appearance of *H. pylori* specific IgA antibodies in the gastric secretions, which prevent *Helicobacter* infection. Since it is a routine matter to conduct

pre-clinical trials of a candidate vaccines for human use in animal models, it is believed that the methodology of the present invention is effective in humans, especially in the prevention and treatment of peptic ulcers, gastritis, gastric malignancies and other conditions arising as a result of the  
5 presence of *H. pylori* and/or *H. heilmanii*.

A - Bacterial cultures and urease purification

The strain of *H. pylori* used in the study originates from a patient with a duodenal ulcer, and has been subcultured on BHI agarose plates to homogeneity. *H. pylori* is cultured in a suitable medium, typically, BHI  
10 (Brain-Heart Infusion) medium, containing 0.25% yeast extract and 10% fetal calf serum and supplemented with 0.4% *Campylobacter* selective complement (Skirrow supplement; Oxoid 69). The bacteria are incubated overnight under microaerophilic conditions at 37°C in bottles that are then sealed and shaken at 37°C for 2 to 3 days to produce a liquid culture. A  
15 culture may also be prepared in agarose plates consisting of BHI with 0.25% of yeast extract and 5% of sheep blood under microaerophilic conditions at 37°C for 3 days. The quantity of bacteria is determined by optical density of the BHI solution at 660 nm, with one optical density unit corresponding to 10<sup>8</sup> bacteria. Cultures on agarose plates are first  
20 resuspended in 154mm NaCl.

One currently preferred source of polyaminoacid displaying urease epitopes is purified urease, e.g., *H. pylori* urease obtained by following the general method of Dunn et al. J. Biol. Chem. 265, 9464-9469, modified as described below. Following culturing, the *H. pylori* is harvested in water,  
25 spun vortexed and spun again to produce a supernatant. The solution containing the urease activity of *H. pylori* (assessed by rapid urease test, see below) is then chromatographed on a CL-6B sizing column and the fractions which present a strong urease activity are pooled and dialyzed overnight and again chromatographed on an anion exchanger gel. The  
30 fractions are eluted in increasing NaCl buffer and the collected fractions with a strong urease activity are individually submitted to a SDS gel followed by Coomassie staining. Two distinct bands corresponding to a

molecular weight of about 63 and about 29 kDa are identified as urease. The fractions containing urease are pooled to give purified *H. pylori* urease having a purity in the region of 95% to 99%.

B - Oral immunization with urease purified from *H. pylori*

5 While it is preferred to employ purified *H. pylori* urease obtained as described as the antigenic material, it will be understood that it is also possible to use, as the antigenic material, any urease or subunit of urease, either naturally occurring or obtained by recombinant DNA techniques, as well as digested fragment thereof, fusion proteins comprising the fragments or the  
10 whole urease, truncated urease constructs, or other peptide or protein preparations exhibiting urease epitopes which are capable of eliciting a protective immune response to *Helicobacter* infection (see below). Thus, it is possible to employ a urease having a substantial homology with respect to *H. pylori* urease and which is effective in raising a cross-protective  
15 immune response to *Helicobacter*. An example of such a urease is jack bean urease, which possesses about 70% homology with *H. pylori* urease. The invention is therefore not limited to the use of intact urease, and covers the use of any polyaminoacid preparation which displays urease epitopes and is effective to generate a protective immunological response in a host to  
20 *Helicobacter* infection. Typically, a urease having a homology of 70-95% homology, for example, 80-90% homology, with respect to *H. pylori* urease, may be employed as the urease antigen in the invention.

A non-limiting list of sources of potentially useful urease preparations includes endogenous urease enzymes of the different  
25 *Helicobacter* species, urease from other bacteria such as *Klebsiella pneumoniae* or *Proteus mirabilis*, and, by analogy, any other urease with the condition that these ureases share cross-reactive epitopes with *H. pylori* urease. The urease genes of all the organisms mentioned above represent a potential tool for expressing recombinant urease products as a whole protein  
30 or as a part thereof.

A non-limiting list of potentially useful urease preparations includes peptides generated from purified urease (the sources are mentioned above),

using physical and/or chemical cleavage procedures (i.e. CnBr) and/or proteolytic cleavage (using proteases e.g. V8-protease, trypsin or others); or peptides synthesized chemically and sharing consecutive epitopes with urease.

5        Other sources of potentially useful epitopes include epitopes identified by their crossreactivity with urease, as the result of screening with anti-urease antibodies. These peptides can be naturally occurring peptides or peptides resulting from chemical synthesis. Furthermore such peptides can result from the expression of recombinant random  
10 oligonucleotide.

Another source of potentially useful epitopes includes epitopes similar to urease as a result of the generation of anti-idiotypic antibodies to urease. Such anti-idiotypic antibodies, generated in any immunocompetent host, are obtained by immunization of this host with anti-urease antibodies,  
15 with the goal of generating antibodies directed against anti-urease antibodies, which share structural homologies with urease.

The discussion herein focuses on the use of urease naturally produced by *H. pylori* (section B). However, it will be appreciated that the urease or subunits or constructs thereof mentioned above, capable of  
20 eliciting the desired protective immune response, may be produced by recombinant DNA techniques well known in the art. The efficacy of particular preparations may be determined by routine administration using animal models, oral administration of the candidate vaccine, and challenge with pathogen using a protocol substantially similar or identical to the  
25 procedure described below.

Table 1 and 2 below and Figures 1-5 describe the results obtained when mice were orally immunized with purified *H. pylori* urease. In this first experiment, administration of the *H. pylori* antigen was carried out by orally administering to the mice *H. pylori* urease purified as described in  
30 section A, and coupled to hydroxyapatite crystals, used as a carrier to enhance M cell binding and uptake. Cholera toxin (Sigma) was given as a mucosal adjuvant. In this experiment, groups of female SPF BALB/c six-

week old mice were each orally immunized with 30 ug of purified *H. pylori* urease coupled to 1 mg of hydroxyapatite plus 10 ug of cholera toxin adjuvant at day 0, 7, 14 and 21. The mice were then challenged twice with  $10^8$  *H. felis*, at day 28 and 30. For comparison purposes, similar female SPF  
5 BALB/c six-week old mice were orally immunized with whole *H. pylori* lysate (sonicate) and 10 ug cholera toxin at day 0, 7, 14 and 21. The mice were challenged at day 28 and 30 with *H. felis*. The *H. pylori* sonicate was prepared by collecting *H. pylori* from cell cultures, pelleting by centrifugation and resuspending the pellet in 0.9% sodium chloride followed  
10 by sonication.

As a control, female SPF BALB/c six-week old mice were orally sham-immunized with 10 ug of cholera toxin and 1 mg of hydroxyapatite at day 0, 7, 14 and 21. All mice were housed, immunized, and challenged in parallel. All mice subject to the study were sacrificed on day 35.

15 C- Oral immunization with recombinant urease subunits of *H. pylori*

Genes encoding the structural A and B subunits of *H. pylori* urease were obtained by polymerase chain reaction (PCR) cloning according to standard procedures, based on previously published sequences [29]. These genes were inserted in a vector (named pEV40) designed for high  
20 expression and easy purification of foreign genes in *E. coli*. Briefly, the foreign gene is inserted downstream of a thermo-repressible promoter, and in frame of a sequence encoding for a repeat of six histidines. An ampR gene is present on this vector for selection of transformants. Under the appropriate temperature conditions, the recombinant protein obtained is  
25 supplemented by six histidines at the N-terminal, which allow for a one-step affinity purification on a nickel column. Both *H. pylori* recombinant urease A and B subunits were expressed separately in *E. coli*, and purified on nickel column to .95% purity.

While it is preferred to employ recombinant *H. pylori* urease  
30 obtained as described above as the antigenic material, it will be understood that it is also possible to use, as the antigenic material, any urease or subunit of urease obtained by recombinant techniques (e.g. fusion protein)

expressing antigenic sites of urease, which is capable of eliciting a protective immune response to *Helicobacter* infection. Thus, it is possible to employ in a construct a urease gene having a substantial homology with respect to *H. pylori* urease and which is effective in raising a cross-  
5 protective immune response to *Helicobacter*. Examples of such a urease is jack bean urease, which possesses about 70% homology with *H. pylori* urease, or *H. felis* urease, which possesses about 88% homology with *H. pylori* urease. The invention is therefore not limited to the use of *H. pylori* urease genes and their gene products, and covers the use of any  
10 recombinant urease, or the subunits thereof, which is effective to generate a protective immunological response in a host to *Helicobacter* infection. Typically, a recombinant urease having a homology of 70-95% homology, for example, 80-90% homology with respect to *H. pylori* urease, may be employed as the recombinant urease antigen in the invention.

15 The discussion herein focuses on the use of recombinant *H. pylori* urease A and B subunits produced by *E. coli* (section C). However, it will be appreciated that recombinant urease or subunits or constructs thereof mentioned above, capable of eliciting the desired protective immune response, may be produced using other recombinant DNA techniques and  
20 other eukaryotic or prokaryotic expression vectors well known in the art.

Table 3, 4 and 5 below and Figure 6 describe the results obtained when mice were orally immunized with recombinant *H. pylori* urease subunits produced in *E. coli*. In this experiment, administration of the *H. pylori* antigen was carried out by orally administering to the mice  
25 recombinant *H. pylori* urease A or B subunits produced in *E. coli* and purified as described above, and coupled to hydroxyapatite crystals, used as a carrier to enhance M cell binding and uptake. Cholera toxin (Sigma) was given as a mucosal adjuvant. In this experiment, groups of female SPF BALB/c six-week old mice were each orally immunized with 30 ug of  
30 recombinant *H. pylori* urease A and B subunit, coupled to 1 mg of hydroxyapatite plus 10 ug of cholera toxin adjuvant at day 0, 8, 14 and 21. The mice were then challenged twice with  $10^8$  *H. felis*, at day 32, 34 and

36. For comparison purposes, similar female SPF BALB/c six-week old mice were orally immunized with 30 ug of recombinant *H. pylori* urease B subunit coupled to hydroxyapatite plus 10 ug cholera toxin at day 0, 8, 14 and 21. The mice were challenged three times, at day 32, 34 and 36, with *H. felis*. As a control, female SPF BALB/c six-week old mice were each orally sham-immunized with 10 ug of cholera toxin and 1 mg of hydroxyapatite at day 0, 8, 14 and 21. The mice were then challenged at day 32, 34 and 36 with *H. felis*. All mice subject to the study were immunized and challenged in parallel. Animals were sacrificed on day 48 (12 days after challenge) or 10 weeks after challenge.

D- Analysis of gastric biopsies, blood, and intestinal secretions

Biopsies were taken from the stomach and blood was obtained from the heart. The intestine were removed and washed with 1mM PMSF (Boeringer) in PBS buffer to obtain intestinal secretions for ELISA analysis.

To evaluate protection against *H. felis* colonization, gastric biopsies from each animal were screened for the presence of *H. felis* by assessing rapid urease activity by the Jatrox HP test (Rohm Pharma), according to the supplier's directions. Briefly, gastric biopsies are immersed in 0.5 ml supplier's mixture of urea and phenol red, a pH indicator. Urease activity generates ammonia and bicarbonate from urea, and is followed by the colometric change of the solution towards a higher absorbance at 550 nm. Urease activity was quantified by spectrophotometric analysis.

Gastric biopsies of each animal included in the experiment described in section B were also cultured on BHI agarose plates, supplemented as above, for the detection of *H. felis*. After incubation for 3 to 10 days in microaerophilic conditions, the presence of *H. felis* was confirmed by Gram staining and determination of urease activity. As a very significant correlation was obtained for the detection of *H. felis* cultures during the first set of experiments (see Table 3), only gastric biopsies urease tests were performed for the detection of *H. felis* in the experiment described in the experiment described in section C. Detection of *H. felis* was confirmed by

microscopy by two independent investigators, using two different stains (acridine orange and cresyl violet).

Blood samples were allowed to clot for 3 hours at RT, and sera harvested and frozen at -20°C until analyzed. Intestinal secretions were  
5 spun for 5 min. at 4°C to remove debris, and kept frozen at -20°C. Serum and intestinal samples of each animal were analyzed by ELISA for evaluation of anti-*Helicobacter* activity, according to standard procedures. Briefly, 96-well plates were coated with a sonicate of *H. pylori*, followed by saturation with 5% fat-free milk. Samples were serially diluted from 1:1  
10 to 1:1000 and incubated overnight at 4°C on ELISA plates. Biotinylated anti-mouse IgG (serum) and anti-mouse IgA, followed by streptavidin-Horseradish peroxidase was used for the determination of the antibody levels.

The results of *H. felis* challenges following immunizations with  
15 purified *H. pylori* urease are set out in Tables 1-3 and Figures 1-4 and the results of *H. felis* challenges following immunizations with recombinant *H. pylori* urease A and B subunits are set out in Tables 4-6 and Figures 5 and 6.



TABLE 1

mouse		urease	culture	Immunoglobulins			
number	Immunization	test	Gram	Serum		Intestinal secretion	
		12h		Ig	IgG	Ig	IgA
1	Urease+HF	+	<i>H felis</i>	27	0	25	258
2	Urease+HF	0	0	264	273	221	246
3	Urease+HF	0	0	84	44	318	354
4	Urease+HF	+	<i>H felis</i>	81	42	12	5
5	Urease+HF	0	0	98	137	126	234
6	Urease+HF	+	0	968	2093	31	22
7	Urease+HF	0	0	98	0	96	34
8	Urease+HF	0	0	247	1010	214	128
9	Urease+HF	0	0	N.D.	N.D.	48	23
10	Urease+HF	0	0	50	0	124	99
11	Urease	0	0	319	205	44	53
12	Urease	0	0	14	0	86	87

13	Urease	0	0	0	0	0	0
14	Urease	0	0	0	0	43	61
15	Urease	0	0	58	0	110	127
16	Urease	0	0	140	63	21	37
17	Urease	0	0	84	240	114	280
18	Urease	0	0	N.D.	N.D.	93	148
19	Urease	0	0	45	0	135	216
20	Urease	0	0	261	197	161	261
21	CT+HF	0	0	0	0	0	2
22	CT+HF	+	<i>H felis</i>	63	0	310	303
23	CT+HF	+	<i>H felis</i>	90	0	N.D.	N.D.
24	CT+HF	+	<i>H felis</i>	31	0	150	192
25	CT+HF	+	<i>H felis</i>	197	250	250	440
26	CT+HF	+	<i>H felis</i>	105	135	214	138
27	CT+HF	+	<i>H felis</i>	140	47	109	55
28	CT+HF	+	0	0	0	16	15
29	CT+HF	+	<i>H felis</i>	0	0	0	0
30	CT+HF	+	<i>H felis</i>	N.D.	N.D.	N.D.	N.D.
31	HP sonicate+HF	+	<i>H felis</i>	0	0	76	103
32	HP sonicate+HF	+	<i>H felis</i>	77	0	11	33
33	HP sonicate+HF	+	<i>H felis</i>	549	748	57	36
34	HP sonicate+HF	0	0	660	153	180	286
35	HP sonicate+HF	+	<i>H felis</i>	730	192	0	5
36	HP sonicate+HF	+	<i>H felis</i>	32	0	5	64
37	HP sonicate+HF	0	0	400	400	312	1149
38	HP sonicate+HF	+	<i>H felis</i>	1007	1360	149	26
39	HP sonicate+HF	0	0	220	186	133	122
40	HP sonicate	0	0	873	1016	352	514
41	HP sonicate	0	0	727	899	126	191
42	HP sonicate	0	0	109	68	44	83
43	HP sonicate	0	0	147	949	167	97
44	HP sonicate	0	0	845	1094	246	64
45	HP sonicate	0	0	1217	1198	210	157
46	HP sonicate	0	0	81	0	256	218
47	HP sonicate	0	0	329	210	241	276
48	HP sonicate	0	0	1049	737	197	211

SUBSTITUTE SHEET

In Table 1, which refers to the experiment described in section B, "h" means hours, "Ig" means immunoglobulin, "ND" means "not determined", "urease + HF" means that the mice were immunized with urease (coupled to hydroxyapatite, with cholera toxin) and then challenged with *H. felis*, "urease" means that the mice were immunized with urease (coupled to hydroxyapatite, with cholera toxin) and not challenged, "CT+HF" means that the mice were sham-immunized with cholera toxin and challenged with *H. felis*, "HP sonicate + HF" means that the mice were immunized with *H. pylori* sonicate with cholera toxin and challenged by *H. felis*, and "HP sonicate" means that the mice were immunized with *H. pylori* sonicate with cholera toxin and not challenged. In Table 1, the numbers for the antibody results are given as a measure of absorbance at 595 nm multiplied by 1000. The background measured in absence of the antibodies, was subtracted.

The results of experiment described in section B obtained on the basis of the gastric biopsies urease tests and on Gram staining of *H. felis* cultures are set out in Table 2. Infection was defined by mice with one or more markers of colonization by *H. felis*, including urease test or Gram staining of cultures.

TABLE 2

Immunization	Challenge	% infected	% protected
Urease	<i>H. felis</i>	3/10 (30%)	7/10 (70%) *
Sonicate	<i>H. felis</i>	6/9 (66%)	3/9 (33%) **
CT	<i>H. felis</i>	9/10 (90%)	1/10 (10%)

\* p=0.0198 (two tailed Fisher exact test) compared to CT control

\*\* p=0.303 (two tailed Fisher exact test) compared to CT control

It will be seen from the results set out in Tables 1 and 2 that statistically significant protection against *H. felis* challenge is obtained with oral immunization using *H. pylori* urease as compared to that obtained

using either *H. pylori* sonicate or cholera toxin. Referring to Table 2, it will be seen that from a total of 10 immunized animals, only 3 became infected, as compared to 6 of the animals immunized with *H. pylori* sonicate and 9 of the animals immunized with cholera toxin. Table 2 shows that 70% of the animals were protected from challenge by *H. felis* as compared to 33% of the animals immunized with *H. pylori* sonicate and 10 of the animals immunized with cholera toxin and then subjected to *H. felis* challenge. In other words, 90% of the control mice exposed to *H. felis* became infected by that pathogen whereas, in contrast, in mice immunized with *H. pylori* urease 28 days before exposure to *H. felis*, the infection rate was only 30%. This represents a significant reduction in infection ( $p=0.0198$  in the Fisher exact test, as compared to the control mice). When the mice were orally immunized with *H. pylori* sonicate, the infection rate was 67% (not significant versus the control). The protection obtained using *H. pylori* urease is unexpected and could not have been predicted on the basis of the results observed using *H. pylori* sonicate.

Referring to Figures 1-4, Figure 1 represents graphically the results of tests for antibodies in serum (IgG) and intestinal secretion (IgA) in mice not protected after immunization with urease. These are mice numbers 1, 4 and 6 appearing in Table 1, and constitute Group A. Figure 2 shows the antibody response of mice that were protected after immunization with urease (Group B), i.e. mice 2, 3, 5 and 7-10.

Figures 3 and 4 relate to the results obtained with mice numbers 31-39. Figure 3 (Group C) depicts antibody responses of mice not protected after immunization with *H. pylori* sonicate (mice numbers 31, 32, 33, 35, 36 and 38) and Figure 4 (Group D) depicts the antibody responses of mice protected after immunization with *H. pylori* sonicate (mice numbers 34, 37 and 39). It is of interest to note with respect to Figures 3 and 4 that the IgA antibody responses (but not IgG) are higher in the mice exhibiting protection than in the mice that are not protected, suggesting a correlation between protection and IgA response. Serum IgG responses did not exhibit

**SUBSTITUTE SHEET**

a correlation. Mucosal IgA but not serum IgG antibodies are known to play a role in protection against bacterial infections of the gut [3].

The results of the correlation between the detection of *H. felis* in gastric biopsies by urease tests and by cultures are set out in Table 3.

5

**TABLE 3**

	Urease Test +	Urease Test-	Total
<i>H. felis</i> culture +	16	0	16
<i>H. felis</i> culture -	2	30	32
Total	18	30	48

10

Two-tailed Fisher's Exact Test:  $p < 0.0001$

Table 3 shows that a very significant correlation exists between the results of urease tests performed on gastric biopsies and the identification of *H. felis* infection. In the next experiments, urease tests were preferred for the diagnosis of *H. felis* infection in mice, due to its better sensitivity. This approach allowed duplication of urease tests with larger fragments of the stomach of each mouse, and a further increase in the sensitivity of the urease test. Furthermore, the use of the method with the highest sensitivity prevent an overestimation the protection obtained by the vaccine preparation to be tested. When positive culture is used as the standard for infection, the protection induced after urease immunization during the experiment depicted in section B is as significant as with the combined use of urease test and culture ( $p=0.021$  versus  $p=0.019$ ).

The results of the experiments described in section C (recombinant urease subunits), obtained on the basis of the gastric biopsies urease tests, are set out in Table 4, 5 and 6 and depicted in Figure 6.

TABLE 4

Immunization	mice n°	Urease test	Infection
CT	20	0.49	+
	21	0.31	+
	22	0.62	+
	23	0.67	+
	24	0.55	+
	50	0.50	+
	51	0.37	+
	52	0.29	+
	53	0.79	+
	54	0.32	+
ureA + HAP + CT	40	0.67	+
	41	0.48	+
	42	0.42	+
	43	0.65	+
	44	0.56	+
	45	0.52	+
	46	0.33	+
	47	0.63	+
	48	0.22	+
	49	0.37	+
ureB + HAP + CT	25	0.15	-
	26	0.07	-
	27	0.03	-
	28	0.64	+
	29	0.13	-
	30	0.02	-
	31	0.66	+
	32	0.00	-
ureA + HAP + CT	68	0.00	-
	69	0.07	-
	70	0.42	+
	71	0.00	-
	72	0.00	-
ureB + HAP + CT	73	0.37	+
	74	0.00	-
	75	0.37	+
	76	0.00	-
	77	0.00	-
	78	0.00	-
	79	0.39	+
	80	0.00	-
	81	0.37	+
	82	0.00	-

SUBSTITUTE SHEET

In Table 4, "CT" means cholera toxin; "UreA" means recombinant *H. pylori* urease A subunit; "UreB" mean recombinant *H. pylori* urease B subunit; and "HAP" means hydroxyapatite crystals. Mice 20 to 54 were sacrificed 12 days post challenge and mice 68 to 82 10 weeks (106 days) post challenge. The results of the urease test performed from biopsies of the stomach of each animal are expressed as OD values at 550 nm. The positive and negative signs depicts the final status of infection of each animal, according to the positivity or negativity of the urease test for detection of *H. felis*. Positivity: OD550 values >0.2

10

---

TABLE 5: Protection as measured 12 days post challenge

<u>Immunization</u>	<u>Challenge</u>	<u>% infected</u>	<u>% protected</u>
Urease A subunit	<u>H. felis</u>	10/10 (%)	0/10 (0%)
Urease B subunit	<u>H. felis</u>	3/10 (30%)	7/10 (70%) *
CT	<u>H. felis</u>	10/10 (100%)	0/10 (0%)

\* p=0.0031 (two tailed Fisher exact test) compared to CT control

---

TABLE 6: Protection as measured 10 weeks post challenge

<u>Immunization</u>	<u>Challenge</u>	<u>% infected</u>	<u>% protected</u>
Urease A subunit	<u>H. felis</u>	1/5 (20%)	4/5 (80%) *
Urease B subunit	<u>H. felis</u>	4/10 (40%)	6/10 (60%) **

\* p=0.003 (two tailed Fisher exact test) compared to CT control

\*\* p=0.01 (two tailed Fisher exact test) compared to CT control

---

25

It will be seen from the results set out in Tables 4, 5 and 6 that statistically significant protection against *H. felis* challenge is obtained with oral immunization using recombinant *H. pylori* urease B subunit as compared to that obtained using either recombinant *H. pylori* urease A subunit or cholera toxin. Referring to Table 4, it will be seen that, 12 days post challenge, from a total of 10 immunized animals, only 3 were found infected in the urease B subunit group, as compared to all 10 animals

**SUBSTITUTE SHEET**

immunized with *H. pylori* A subunit of urease and 10 out of 10 of the animals immunized with cholera toxin. Table 4 shows that 70% of the animals were protected from challenge by *H. felis* as compared to 0% of the animals immunized with *H. pylori* urease A subunit and 0% of the animals immunized with cholera toxin and then subjected to *H. felis* challenge. In other words, 100% of the control mice challenged with *H. felis* became infected whereas, in contrast, in mice immunized with recombinant *H. pylori* urease B subunit the infection rate was only 30%. This represents a significant reduction in infection ( $p=0.0031$ , Fisher exact test) as compared to the control mice.

The fact that the protection observed with *H. pylori* urease is entirely conferred by immunization with the B subunit of urease, and that the A subunit has no such effect, was not expected on the basis of our experiment with purified urease. This definition of the roles of the 2 structural subunits of urease in the development of a protective immune response is therefore novel. The protection obtained using recombinant urease B subunit, which is enzymatically inactive also teaches that non-toxic forms of urease can be used as oral vaccine against *Helicobacter* infection. Furthermore these results strongly suggest that recognition of the active site is not required for protection, as an inactive urease B subunit is very unlikely to induce antibodies that will recognize and inhibit the catalytic site of native urease.

Referring to Table 6, it will be seen that, when mice are sacrificed 10 weeks post infection, 60% (6 mice out of 10) of the animals immunized with urease B subunit and 80% (4 mice out of 5) of the animals immunized with *H. pylori* urease B subunit were protected against *H. felis* infection. The fact that protection obtained through immunization with urease B subunit lasts over time and that immunization with urease A induces a protection which is displaced compared to the one induced by urease B subunit could not be expected from our experiment with purified urease or with other experiment performed earlier. The fact that urease B subunit immunization confers protection definitely proves that recognition of the

**SUBSTITUTE SHEET**



active site is not required for protection. Figure 6 summarizes results obtained after oral immunization with recombinant urease A and B subunits (described in Tables 5 and 6).

The present invention also provides vaccine compositions suitable  
5 for the prevention of *Helicobacter* infection. The compositions comprise an effective amount of a urease antigen, preferably *H. pylori* urease or recombinant *H. pylori* urease subunits, capable of eliciting in a host a protective immune response to *Helicobacter* infection, in association with a pharmaceutically acceptable carrier or diluent.

10 The vaccines of the invention are administered in amounts readily determined by persons of ordinary skill in this art. Thus, for adults a suitable dosage will be in the range of 10 ug to 100 milligrams, for example 50 ug to 50 mg. Similar dosage ranges will be applicable for children. Carrier systems in humans may include enteric release capsules  
15 protecting the antigen from the acidic environment of the stomach, and including urease antigen in a insoluble form as fusion proteins. The vaccine can be administered as a primary prophylactic agent in adults or in children, as a secondary prevention, after successful eradication of *H. pylori* in an infected host, or as a therapeutic agent in the aim to induce an immune  
20 response in the host susceptible to contribute to the eradication of *H. pylori*.

As noted above, a suitable mucosal adjuvant is cholera toxin. Others which may be used as muramyl dipeptide or its derivatives, non-toxic derivatives of cholera toxin, including its B subunit, and/or conjugates or genetically engineered fusions of the urease antigen plus cholera toxin or its  
25 B subunit. Other suitable delivery methods include biodegradable microcapsules or immune stimulating complexes (ISCOM'S) or liposomes, genetically engineered attenuated live vectors such as viruses or bacteria, and recombinant (chimeric) virus-like particles, e.g. bluetongue. The amount of mucosal adjuvant employed depends on the type of mucosal adjuvant  
30 used. For example, when the mucosal adjuvant is cholera toxin, it is suitably used in an amount of 5 ug to 50 ug, for example 10 ug to 35 ug. When used in the form of microcapsules, the amount used will depend on

the amount employed in the matrix of the microcapsules to achieve the desired dosage. The determination of this amount is within the skill of a person of ordinary skill in this art. Suitable carriers for the vaccines of the invention are enteric coated capsules and polyactide-glycolide microspheres.

5 Suitable diluents are 0.2N  $\text{NaHCO}_3$  and/or saline.

Particulate hydroxylated calcium phosphate (HCP) is especially useful as a carrier for the *H. pylori* urease to be applied to mucosal surfaces. It is believed that the *H. pylori* urease-hydroxylated calcium phosphate conjugate is transported across epithelium where it raises a poly  
10 Ig immune response. Preferably, the hydroxylated calcium phosphate is in the form of microparticles suitable for the transport across the epithelium, particularly by cells specialized for this purpose (M cells). A preferred form of hydroxylated calcium phosphate is hydroxyapatite, a commercially available crystalline hydroxylated calcium phosphate  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ .

15 Commercially available hydroxyapatite generally consists of slab-like crystals that are chemically and physically analogous to inorganic hydroxyapatite in normal bone tissue. Ingestion of hydroxyapatite should therefore be safe, as evidenced by the existence of nutritional calcium/phosphorous supplements derived from ground bone, which are  
20 designed to be ingested. Commercially-high resolution hydroxyapatite (from CalBioChecm) consists of crystals varying widely in size. Crystals over 1  $\mu\text{m}$  in length are unlikely to be taken up by M cells. Therefore, for use in the invention, commercial hydroxyapatite crystals are broken into small, relatively uniform crystalline fragments such as by sonication. Preferably, a  
25 substantial proportion of the hydroxyapatite is present as fragments of about 0.01-0.0  $\mu\text{m}$ . Fragmentation may be measured either by electron microscopy or light scattering, using standard techniques.

Preferred modes of administration of the *H. pylori* urease antigen are orally, nasally, rectally or ocularly. Oral administration can provide delivery  
30 to other G.I. mucosa including the intestinal mucosa.

The vaccines of the present invention may be administered to a mucosal surface in the form of an aerosol, suspension, capsule and/or

suppository. The method of administration will be readily apparent to a person of ordinary skill in this art.

The present invention further includes the passive immunization of mammals, including humans, against *Helicobacter* infection. This is  
5 achieved by administering to a mucosal surface of the patient an effective amount of a urease specific antibody. Preferably, an effective amount of a *H. pylori* urease specific IgA monoclonal antibody.

Since the urease of *H. pylori* is shown to represent the antigen involved in inducing protective immunity, a further aspect of the invention  
10 is the use of *H. pylori* urease as a diagnostic reagent to measure the immune response of persons who have received a vaccine based on urease or to determine whether an individual is immune or susceptible (and thus in need of vaccination). The present invention also includes the use of urease and urease-specific antibodies, to construct assays and kits for diagnosis of  
15 *Helicobacter* immunity, assessment of *Helicobacter* susceptibility, and definition of immune responses to vaccines.

### **EXAMPLES**

The invention will now be further described by reference to the  
20 following non-limiting examples.

#### **a) The Bacterial Strains**

*H. felis* was provided by J. Fo (division of Cooperative Medicine, Mass. Institute of Technology, Boston, USA). *H. pylori* was isolated from patients with ulcer disease (CHUV, Lausanne, Switzerland).

#### **25 b) Bacterial Cultures**

Liquid Culture - Bacteria were cultured on BHI (Brain-Heart Infusion, BioMerieux) liquid medium containing 0.25% of yeast extract (Difco) and 10% of fetal calf serum (Inotech) supplemented with 0.4% of Campylobacter selected complement (Oxoid). The bacteria were incubated  
30 overnight under microphilic conditions at 37°C and then shaken at 37°C for 2 to 3 days.

Culture on Agarose plates - The bacteria were cultured on agar plate consisting of BHI 0.25% of yeast extract and 5% of sheep blood under microphilic conditions at 37°C for 3 days.

Quantification - The quantity of bacteria was determined by the optical density of the BHI solution at 660 nm (1 optical density unit corresponding to 10<sup>8</sup> bacterial).

c) Preparation of sonicates

*H. pylori* was collected from 31 blood agar plates in 0.15 M NaCl and spun 5 minutes at 1400g at 4°C. The pellet was resuspended in 3 ml of NaCl and sonicated for 4 minutes. The amount of proteins was evaluated by a Bradford assay (BioRad Kit according to supplier).

d) Coupling of immunogen to Hydroxyapatite

Immunogen (urease or subunit thereof) was incubated for 1 hour at 4°C with hydroxyapatite. 1.0 mg of hydroxyapatite was used for 30 ug of immunogen per mouse. At the end of the incubation, 10 ug of cholera toxin was added in a final volume of 200ul PBS.

EXAMPLE 1

a) Extraction

*H. pylori* from 30 blood agar plates was harvested in 0.15 M NaCl on ice. The solution was spun 5 minutes at 1400 g at 4°C. The pellet was resuspended in 20 ml of H<sub>2</sub>O and vortexed for 45 seconds (maximum speed). The extract was then spun 20 minutes at 6700 g at 4°C. The supernatant was recovered and the quantity of protein was evaluated (see "Quantification" above) and precipitated with 70% of ammonium sulfate.

b) Purification of urease

The solution was chromatographed on a Sepharose CL-6B column (Pharmacia) with PBS (phosphate buffered saline) as mobile phase. The collected fractions which presented a strong urease activity were pooled and dialyzed overnight at 4°C against 3 liters of PEB (20 nM phosphate buffer, pH 7) and then chromatographed on a Q Sepharose fast flow (Pharmacia) with PEB as mobile phase. The fractions were eluted by 0 to 500 nM NaCl.

gradient. Ten of the collected fractions with a strong urease activity were individually subjected to an SDA gel followed by a Coomassie staining. The 6 fractions presenting 2 distinct bands corresponding to MW-63 and -28 KDa were pooled and were considered as the purified urease.

5

**EXAMPLE 2 (see also section B)**

Mice employed in the immunization studies were lightly anesthetized with ether prior to intragastric immunization. And then, sonicate preparation or purified urease, hydroxyapatite and cholera toxin  
10 was suspended in PBS and 200ul were delivered to the stomach of the respective mice using a polyethylene tubing attached to a hypodermic syringe. This procedure will be referred to as oral immunization.

Three oral immunization protocols were evaluated. These are described below.

15 **Protocol B1 - Vaccination with purified urease**

Female BALB/c six-week old mice (20) were orally immunized with 30 ug of purified of *H. pylori* urease and 1 mg of hydroxyapatite and 10 ug of cholera toxin at day 0, 7, 14 and 21. Ten mice were challenged at day 28 and 30 with  $5 \times 10^7$  and  $10^8$  *H. felis* from liquid culture.

20 **Protocol B2 - Vaccination with Helicobacter sonicates**

Female BALB/c six-week old mice (20) were orally immunized with 2 mg of *H. pylori* sonicate solution at day 0, 7, 14 and 21. Ten mice were challenged at day 28 and 30 with  $5 \times 10^7$  and  $10^8$  *H. felis*.

**Protocol B3 - Control**

25 Female BALB/c six-week old mice (20) were orally immunized with 1 hydrozapatite and 10ug of cholera toxin at day 0, 7, 14 and 21. The mice were challenged at day 28 and 30 with  $5 \times 10^7$  and  $10^8$  *H. felis*.

At day 35 all mice were sacrificed and biopsies from the stomach were taken as well as intestinal secretions and blood.

30

**Protection and evaluation**

To evaluate protection, biopsies were screened for the urease activity by the Jetrox HP test (Rohm Pharma) according to the instructions of the supplier. The urease is quantified by a spectrophotometric measurement at 550 nm. The biopsies were also cultured in the presence of *H. felis* and was  
5 estimated by Gram staining. Gastric antral biopsies were homogenized and diluted (1:10 and 1:1000) in 0.15 M NaCl and plated onto blood agar plates and incubated under microaerophilic conditions at 37°C for 4 to 10 days.

#### 10 ELISA

Intestinal secretions and blood were analyzed by ELISA for the evaluation of antibody titer. The ELISA was carried out as follows. Polystyrene plates (96 wells) were coated with  $\mu\text{g}/\text{well}$  of purified urease at 37°C for 2 hrs. Non specific binding sites were blocked with 5% powdered  
15 milk in PBS 0.1% Tween at 37°C for 30 minutes. The plates were washed once with PBS 0.1% Tween. Blood samples were test at dilution 1:100 and intestinal secretions 1:1. 100ul of each sample were added to the antigen coated plates. After 2 hrs of incubation, plates were washed 3 times with PBS 0.1% Tween. Anti-mouse biotinylated whole antibody from goat and  
20 anti-mouse IgA, IgG and IgM biotinylated (Amersham) were added (100ul) at dilution 1:500 except for IgA (1:250) and incubated at 37°C for 1 hr. The plates were washed 3 times with PBS 0.1% Tween and 100ul of 1:1000 dilution of streptavidin Horseradish peroxidase in PBS 0.1% Tween were added and incubated at 37°C for 30 minutes. The plates were washed  
25 3 times and 50ul of 1:50 dilution of o-phenyl-diamine in citrate buffer pH 5.0 with 1ul/ml of 30%  $\text{H}_2\text{O}_2$  were added and incubated at room temperature for 20 minutes. The absorbance at 495 nm was measured in each well.

#### EXAMPLE 3 (see also section C)

Mice employed in the immunization studies were slightly  
30 anesthetized with ether prior to intragastric immunization. Then, 30  $\mu\text{g}$  recombinant *H. pylori* urease A and B subunit produced in *E. coli* bound hydroxyapatite and supplemented with cholera toxin was suspended in PBS.

and 200ul were delivered to the stomach of the respective mice using a polyethylene tubing attached to a hypodermic syringe. This procedure will be referred to as oral immunization.

Three oral immunization protocols were evaluated. These are  
5 described below.

**Protocol C1 - Vaccination with recombinant urease A subunit**

Female BALB/c six-week old mice (10) were orally immunized with 30 ug of purified recombinant *H. pylori* urease A subunit and 1 mg of hydroxyapatite and 10 ug of cholera toxin at day 0, 8, 14 and 21. Ten  
10 mice were challenged at day 32, 34 and 36 with  $10^8$  *H. felis* from liquid culture.

**Protocol C2 - Vaccination with recombinant urease B subunit**

Female BALB/c six-week old mice (10) were orally immunized with 30 ug of recombinant *H. pylori* urease B subunit and 1 mg of  
15 hydroxyapatite and 10 ug of cholera toxin at day 0, 8, 14 and 21. Ten mice were challenged at day 32, 34 and 36 with  $10^8$  *H. felis* from liquid culture.

**Protocol C3 - Control**

Female BALB/c six-week old mice (10) were orally immunized with  
20 1 mg hydroxyapatite and 10 ug of cholera toxin at day 0, 8, 14 and 21. The mice were challenged at day 32, 34 and 36 with  $10^8$  *H. felis*.

At day 42, or at day 106, mice were sacrificed and multiple biopsies from the stomach were taken.

25 **Protection and Evaluation**

To evaluate protection, biopsies of the corpus and antrum of the stomach were screened for urease activity by the Jatrox HP test (Rohm Pharma) according to the instructions of the supplier. The urease is quantified by a spectrophotometric measurement at 550nm. The total of  
30 corpus and antrum OD values were added to obtain a final OD value for each mouse.

### References

1. Blaser, M.J. "Gastric Campylobacter-like organisms, gastritis and peptic ulcer disease" *Gastroenterology* 1987, 93, 371-383.
- 5 2. Graham, D.Y. "Campylobacter *pylori* and peptic ulcer disease" *Gastroenterology* 1989, 96, 615-625.
3. Parsonnet, J. et al "Helicobacter *pylori* infection in intestinal and diffuse-type gastric adenocarcinomas" *J. Natl. Cancer Inst.* 1991, 83, 640-643.
- 10 4. Marshall, B.J. et al "Attempt to fulfill Koch's postulate for *pyloric* Campylobacter" *Med. J. Aust.* 1985, 142, 436-439.
5. Morris, A. et al "Ingestion of Campylobacter *pyloridis* causes gastritis and raised fasting gastric pH" *Am. J. Gastroenterology*, 1987, 82, 192-199.
- 15 6. Engstrand, L. et al "Inoculation of barrier-born pigs with *Helicobacter pylori*: a useful animal model for gastritis type B" *Infect. Immun.* 1990, 58, 1763-1768.
7. Fox, J.G. et al "Gastric colonization by campylobacter *pylori* subsp. *mustelae* in ferrets" *Infect. Immun.* 1988, 56, 2994-2996.
- 20 8. Fox, J.G. et al "*Helicobacter mustelae*-associated gastritis in ferrets: an animal model of *Helicobacter pylori* gastritis in humans" *Gastroenterology* 1990, 99, 352-361.
9. Lee, A. et al "A small animal model of human *Helicobacter pylori* active chronic gastritis" *Gastroenterology* 1990, 99, 1315-1323.
- 25 10. Fox, J.G. et al "*Helicobacter felis* gastritis in gnotobiotic rats: an animal model of *Helicobacter pylori* gastritis" *Infect. Immun.* 1991, 59, 785-791.
11. Eaton, K.A. et al "Campylobacter *pylori* virulence factors in gnotobiotic piglets" *Infect. Immun.* 1989, 57, 1119-1125.
- 30 12. Peterson, W.L. "*Helicobacter pylori* and peptic ulcer disease" *N. Engl. J. Med.* 1991, 324, 1043-1048.



13. Czinn, S.J. and Nedrud, J.G. "Oral immunization against *Helicobacter pylori*" *Infect. Immun.* 1991, 2359-2363.
14. Brandtzaeg, P. "Role of H chain and secretory component in receptor-mediated glandular and hepatic transport of immunoglobulins in man" *Scand. J. Immunol.* 1985, 22, 111-146.
15. Brandtzaeg, P. "Production and secretion of immunoglobulins in the gastrointestinal tract" *Ann. Allergy* 1987, 59, 21-39.
16. Wyatt, J. I. "Local immune response to gastric campylobacter in non-ulcer dyspepsia" *J. Clin. Path.* 1986, 39, 863-870.
- 10 17. Lee, A. et al "Pathogenicity of *Helicobacter pylori*: A perspective" *Infect. Immun.* 1993, 61, 1601-1610.
18. Pallen, M.J. and Clayton, C.L. "Vaccination against *Helicobacter pylori* urease, letter" *Lancet*, 1990, 336, 186.
19. Evans, D.J. et al "Urease-associated heat shock protein of *Helicobacter pylori*" *Infect. Immun.* 1992, 60, 2125-2127.
- 15 20. Ferrero, R.L. and Lee, A. "The importance of urease in acid protection for the gastric-colonizing bacteria *Helicobacter pylori* and *Helicobacter felis* sp. nov." *Microb. Ecol. Health Dis.* 1991, 4, 121-134.
21. Chen, et al "Immunization against gastric *Helicobacter* infection in a mouse/*Helicobacter felis* model, letter" *Lancet*, 1992, 339, 1120-1121.
- 20 22. Czinn, S. et al "Oral immunization protects germ-free mice against infection from *Helicobacter felis*". Proceedings of the DDW, American Gastroenterological Association. May 10-13, 1992, 1321, A-331.
23. Guo, M. and Liu, P.V. "Serological specificities of ureases of *Proteus* species" *J. Gen. Microbiol.* 1965, 136, 1995-2000.
- 25 24. Michetti, P. et al "Specificity of mucosal IgA response in Balb/c mice following *H. felis* or *H. pylori* challenges" Proceedings of the DDW, American Gastroenterology Association. May 10-13, 1992, 1001, A-251.
25. Davin, C. et al. "*H. pylori* urease elicits protection against *H. felis* infection in mice" Proceedings of the DDW, American Gastroenterology Association, May 16-19, 1993, 1213, A-304.
- 30

26. Pallen, M.J. and Clayton, C.L. "Vaccination against *Helicobacter pylori* urease". Lancet 1990, 336, 186-7.
27. Pimentel, J.L. and Cook, M.E. "Improved growth in the progeny of hens immunized with jackbean urease" Poultry Sci. 1988, 64, 434-439.
- 5 28. Labigne, A. "Sequences of nucleotides coding for a protein having an urease activity". EPO patent application #EPO 0 367 644 A1, 1989. Intl publication # WO90/04030, 1990.
29. Clayton, C.L. et al. "Nucleotide sequence of two genes from *Helicobacter pylori* encoding for urease subunits". Nucleic Acid Res. 1990,  
10 18, 362.
30. McGhee, J.R. and Kyono, H. "New perspectives in vaccine development: mucosal immunity to infections". Infect Agents Dis. 1993, 2, 55-73.

**WHAT IS CLAIMED IS:**

- 1 1. A method of eliciting in a mammalian host a protective immune  
2 response to *Helicobacter* infection, said method comprising the step of:  
3 administering to a mucosal surface of said mammal an  
4 immunogenically effective amount of a polyaminoacid preparation  
5 presenting a sufficient number of epitopes exhibited by a urease endogenous  
6 to said *Helicobacter* organism to elicit a protective immune response to  
7 infection by said organism.  
8
- 1 2. A method according to claim 1, wherein said preparation comprises an  
2 intact urease purified from an organism.
- 1 3. A method according to claim 1, wherein said preparation comprises  
2 peptides homologous with enzymatically inactive portions of the aminoacid  
3 sequences of a urease.
- 1 4. A method according to claim 1, wherein said preparation comprises  
2 peptides non-homologous with the aminoacid sequences of a urease and  
3 displaying epitopes cross-reacting of a urease.
- 1 5. A method according to claim 1, wherein said preparation comprises *H.*  
2 *pylori* urease.
- 1 6. A method according to claim 1, wherein said preparation comprises at  
2 least subunits of a urease, with or without enzymatic activity.
- 1 7. A method according to claim 1, wherein said preparation comprises  
2 anti-idiotypic antibodies to a urease.
- 1 8. A method according to claim 1, wherein said preparation comprises  
2 peptides immunologically cross-reacting with urease.

**SUBSTITUTE SHEET**

1 9. A method according to claim 3 and 9, wherein said peptides are  
2 obtained by chemical synthesis.

1 10. A method according to claim 1, wherein said preparation comprises  
2 urease antigens producing using DNA recombinant techniques.

1 11. A method according to claim 1, wherein said preparation comprises  
2 subgenic fragments of urease produced with recombinant techniques.

1 12. A method according to claim 1, wherein said preparation comprises  
2 urease subgenic fragments produced as genetically fused proteins.

1 13. A method according to claim 12, wherein said fused proteins comprise  
2 cholera toxin subunits.

1 14. A method according to claim 1, wherein said preparation is  
2 administered in association with a mucosal adjuvant.

1 15. A method according to claim 14, wherein said mucosal adjuvant is  
2 cholera toxin.

1 16. A method according to claim 1, wherein said mammalian host is  
2 human.

1 17. A method according to claim 1, wherein said preparation is  
2 administered in association with a hydroxylated calcium phosphate.

1 18. A method according to claim 17, wherein said hydroxylated calcium  
2 phosphate is hydroxyapatite.

1 19. A method according to claim 18, wherein said hydroxyapatite is in the  
2 form of particles suitable for transport across epithelium.

1 20. A method according to claim 1, wherein said urease is administered  
2 orally, nasally, rectally or ocularly.

1 21. A vaccine for inducing a protective immune response to *Helicobacter*  
2 infection in a mammal, the vaccine comprising a polyaminoacid preparation  
3 presenting epitopes exhibited by a urease endogenous to said *Helicobacter*  
4 organism disposed in a pharmaceutically acceptable carrier or diluent.

5

22. The vaccine of claim 21, further comprising a mucosal adjuvant.

23. A method of imparting to a mammal passive protection to  
*Helicobacter* infection, the method comprising administering to a mucosal  
surface of said mammal an immunologically effective amount of a urease-  
specific IgA antibody produced in a host by immunization with a urease  
which elicits a protective immune response to *Helicobacter*.

24. A method according to claim 23, wherein said antibody is a  
*Helicobacter pylori* urease specific IgA antibody.

25. A method according to claim 24, wherein said mammal is human.


26. A method for assessing the endogenous immune response of a  
mammal infected by *Helicobacter* organism, the method comprising  
determining in a sample from the gastrointestinal tract of said mammal the  
presence of antibody reactive with epitopes exhibited by urease endogenous  
to said *Helicobacter* organism.

27. A method according to claim 27, comprising the additional step of administering a *Helicobacter* vaccine to said mammal prior to said administration.


1/4

**Fig. 1**

**GROUP A: MICE NOT PROTECTED AFTER IMMUNIZATION WITH UREASE**



**GROUP B: MICE PROTECTED AFTER IMMUNIZATION WITH UREASE**




**Fig. 2**


2/4

**Fig. 3**

GROUP C: MICE NOT PROTECTED AFTER IMMUNIZATION WITH H.p.  
SONICATE




GROUP D: MICE PROTECTED AFTER IMMUNIZATION WITH  
H.p SONICATE

**Fig. 4**

SUBSTITUTE SHEET



3/4



**Fig. 5**

immunization :	<i>H. pylori</i> sonicate	<i>H. pylori</i> urease	control
----------------	------------------------------	----------------------------	---------

protected :	3/9	7/10	1/10
-------------	-----	------	------

\* Two-tailed Fisher Exact Test

4/4

**Fig. 6A****Fig. 6B**

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/03059

## A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 39/106, C 07 K 15/04, C 12 N 9/78, C 12 N 15/55,  
G 01 N 33/573, G 01 N 33/569

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K, C 12 N, G 01 N 33/00, C 07 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A1, 93/07 273 (INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)) 15 April 1993 (15.04.93), claims 18, 19, 34, 37, 38.	1-27
A	EP, A1, 0 367 644 (INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)) 09 May 1990 (09.05.90), claims 16-19, 26-28 (cited in the application).	1-27
P, A	CHEMICAL ABSTRACTS, vol. 118, no. 9, issued 01 March 1993 (Columbus, Ohio, USA), K. NAGATA et al. "Monoclonal	7, 23- 26



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 "&" document member of the same patent family

Date of the actual completion of the international search

27 January 1994

Date of mailing of the international search report

25 -03- 1994

Name and mailing address of the ISA

European Patent Office, P.B. 3818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+ 31-70) 340-3016

Authorized officer

SCHNASS e.h.

## INTERNATIONAL SEARCH REPORT

-2-

 International Application No  
 PCT/EP 93/03059

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>antibodies against the native urease of helicobacter pylori: synergistic inhibition of urease activity by monoclonal antibody combination.",            page 637, abstract no. 78946n            &amp; Infect. Immun. 1992, 60(11), 4826-31.</p>	
A	<p>---            CHEMICAL ABSTRACTS, vol. 114, no. 5, issued 4 February 1991 (Columbus, Ohio, USA), P.R. HAWTIN et al. "Investigation of the structure and localization of the urease of Helicobacter pylori using monoclonal antibodies."            page 325, abstract no. 38381k &amp; J.Gen.Microbiol. 1990, 136(10), 1995-2000.</p>	<p>7,23-26</p>
A	<p>---            CHEMICAL ABSTRACTS, vol. 112, no. 17, issued 23 April 1990 (Columbus, Ohio, USA), C.L. CLAYTON et al. "Nucleotide sequence of two genes from Helicobacter pylori encoding for urease subunits" page 175-6, abstract no. 152675t            &amp; Nucleic Acids Res. 1990, 18(2), 362            (cited in the application).</p> <p>----</p>	<p>10</p>